333 results about "Blood plasma" patented technology

This invention belongs to the field of diagnostic testing technology. Addressing the problem that existing gestational diabetes screening methods may miss the optimal time for early intervention, leading to the failure to promptly detect and manage some potentially hyperglycemic pregnant women, increasing the risk of adverse maternal and fetal outcomes, this invention proposes a plasma metabolic biomarker for the early diagnosis or prediction of gestational diabetes and its application. This plasma metabolic biomarker is at least one of L-lysine, propargylglycine, N6-acetyl-L-lysine, cyclic leucine, and glycine-deoxycholic acid. The five plasma metabolic biomarkers provided by this invention can be applied to the early diagnosis or prediction of gestational diabetes, and are of great significance for the prevention or treatment of gestational diabetes.

本发明实施例公开了一种基于蛋白质组学的脓毒症休克患者液体管理策略预测方法。所述方法包括：收集脓毒症休克患者的血浆样本，检测蛋白质标志物的表达水平，所述蛋白质标志物为GAL、NFASC、MICB_MICA、MAP2K6、JCHAIN和CSF3的组合；基于亚组识别模型计算效益得分，获得脓毒症休克患者的液体管理策略结果。本发明通过收集脓毒症休克患者的临床数据和蛋白质表达数据，采用LASSO回归分析，构建基于上述蛋白质标志物的亚组识别模型，进而获得效益评分，基于效益评分能预测患者液体管理策略方案的适用性，为脓毒症休克患者的液体治疗提供了可靠的方案，实现个体化和精准的液体治疗，在临床具有较好的应用前景。

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke. By constructing a mouse model of heatstroke-induced myocardial injury and observing indicators such as rectal temperature, blood routine tests, blood biochemistry, oxidative stress, and cardiac function, this invention found that lemon balm glycosides can significantly reduce the increase in rectal temperature caused by heatstroke in mice, increase the content of red blood cells and albumin in plasma, and reduce the level of oxidative stress in myocardial cells. Therefore, the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke is proposed.

This invention relates to the fields of biomedical technology and biological model construction technology, and discloses an ANCA-associated vasculitis glomerular endothelial cell injury model, its construction method and application, and the application of BACH1 inhibitors. The method includes: (1) activating neutrophils sequentially with tumor necrosis factor α and immunoglobulin G to obtain a culture medium containing activated neutrophils; wherein the immunoglobulin G is immunoglobulin G isolated and purified from the plasma of patients with ANCA-associated vasculitis; (2) co-culturing the culture medium containing activated neutrophils with human glomerular endothelial cells to obtain the cell injury model. The cell injury model provided by this invention can verify the role of neutrophil adhesion characteristics in endothelial cell injury, and at the same time, the cell injury model can better simulate the immune microenvironment of ANCA-associated vasculitis glomerular endothelial cells in vivo.

The application provides a full-passive microfluidic whole blood sample preparation device, which comprises, from bottom to top, a bottom support layer, a bottom hydrophilic layer, a bottom adhesive layer, a middle main body layer, a liquid outlet channel layer, an upper surface hydrophilic layer of the liquid outlet channel, a first intermediate adhesive layer, an upper layer main body layer, a second intermediate adhesive layer, a top cover layer and a product collection and storage cavity sealing patch which are laminated and assembled in sequence. The application does not need any external driving force or active surface treatment, and only relies on the material properties and ingenious structure design, so that the plasma / serum can be automatically and efficiently separated from trace whole blood, and the application has the advantages of simple structure, low cost, convenient operation, one-time use, instant detection application and the like.

In accordance with at least one aspect of this disclosure, a method for preparing a patient for a diagnostic procedure and / or for receiving a therapy using a disease targeted drug is provided. The method can include the steps of a) identifying one or more soluble targets detectable in plasma of the patient; and b) extracorporeally removing the soluble targets from the plasma of the patient. Extracorporeally removing the soluble targets from the plasma of the patient can include using plasmapheresis or immunoadsorption to prepare a patient for a procedure using disease targeted treatment or diagnostics. Additionally, or alternatively, dose modulation can be used to proportionally increase the concertation of the diagnostic / treatment agent relative to the concentration of the soluble target in the blood, improving the outcome treatment and diagnostic procedures over conventional methods.

The application provides a kind of nanoparticle, preparation method and its early screening related application of cancer, wherein, nanoparticle includes superparamagnetic nanometer core, cationic polymer modified on the surface of superparamagnetic nanometer core and targeted polypeptide grafted on cationic polymer, the targeted polypeptide can specifically recognize tumor specific antigen protein, and has the modular structure of rigid helix and charge repulsion sequence.The plasma low-abundance protein enrichment nanoparticle provided by the application can be used for the detection of early screening of tumor through liquid biopsy, can significantly improve the detection rate of early tumor, and has important clinical significance.

The application discloses a combined filter for separating plasma from whole blood, comprising a whole blood sample adding chamber, a first combined filter membrane, an intermediate chamber, a second combined filter membrane and a plasma collecting chamber arranged in sequence along a filtering direction of a whole blood sample flow; and the whole blood sample is filtered multiple times through the first combined filter membrane and the second combined filter membrane to obtain a plasma sample. The application further provides a combined filter device and a method for separating plasma from whole blood. The combined filter provided by the application can further improve the recovery rate, recovery quality and recovery efficiency of the whole blood separation plasma, and meets the demand of in-vitro diagnosis on the pretreatment of the whole blood sample.

The present application provides a kind of potassium channel regulator, its preparation method, pharmaceutical composition and application. Specifically provided are compounds as shown in formula V or pharmaceutically acceptable salts thereof. The potassium channel regulator compound of the present application has one or more of the following effect advantages: (1) novel structure; (2) good KCNQ2 / 3 channel opening activity; (3) weak KCNQ4, KCNQ5 opening activity, high KCNQ2 / 3 selectivity; (4) good in vivo efficacy, good protection effect on seizures; (5) low neuro-motor toxicity; (6) high brain-blood ratio; (7) high plasma, brain tissue concentration.

FIELD: pharmacology.SUBSTANCE invention can be used to determine the concentration of an anti-tuberculosis drug in blood serum. The method for determining the concentration of bedaquiline in the blood serum in patients with tuberculosis or mycobacteriosis is that whole blood samples are centrifuged at 3000 rpm for 20 minutes, then the blood plasma is collected in sterile 1.5 mL Eppendorf tubes, then 900 mcL of acetonitrile are added to 300 mcL of plasma and centrifuged at 13500g for 15 minutes, then 1 mL of the supernatant is transferred to a chromatographic vial and make the assay by UHPLC MS / MS using an Athena UHPLC C18, 1.8 mcM, 120A, 2.1×100 mm chromatography column, when using an aqueous solution containing 5 g / L of ammonium acetate, 25 ml / L of concentrated acetic acid, 2 ml / L trifluoroacetic acid as mobile phase A and 100% acetonitrile as mobile phase B, the concentration of bedaquiline is determined using a pre-plotted calibration curve.EFFECT: determination of bedaquiline in human blood plasma in a time not exceeding 6 minutes.1 cl, 9 dwg, 6 tbl

This invention relates to the fields of molecular biology and biomedicine, disclosing plasma-active peptides with antithrombotic effects and their uses. The invention obtains various active peptides from plasma through screening and solid-phase synthesis, and confirms their biological activity through in vitro platelet aggregation experiments and in vivo arterial thrombosis model experiments. Results show that peptides 1957, 1960, and 1961 significantly inhibit collagen-induced platelet aggregation, exhibiting good antiplatelet activity; animal experiments show that peptides 1955, 1957, 1960, and 1961 significantly inhibit arterial thrombosis. These active peptides are derived from endogenous plasma components, belonging to natural antithrombotic substances, possessing good physiological compatibility and safety advantages, and reducing the risk of immunogenicity and adverse reactions. These peptides can exert antithrombotic effects without relying on traditional antiplatelet drugs, providing a new source of active molecules and treatment options for the prevention and treatment of thrombotic diseases.

This invention discloses the application of reagents for detecting biomarker levels in the preparation of products for identifying obstructive sleep apnea. It relates to the field of biomarker technology and aims to overcome the shortcomings of existing technologies that rely on complex polysomnography (PSG) procedures, poor patient compliance, and a lack of effective molecular markers. The biomarkers used in this application consist of CD36 glycoprotein, 9-octadecenal, and protocatechuic acid 3-O-sulfate. This invention enables rapid and objective identification of obstructive sleep apnea by detecting the levels of the above biomarkers in plasma. The procedure is simple and well-accepted by patients. The combined use of multiple biomarkers can improve the accuracy and stability of the identification, making it suitable for screening or auxiliary diagnosis in medical institutions at different levels.

The present invention relates to a syrup containing alectinib or a salt thereof. The present invention provides a syrup containing alectinib or a salt thereof, which is a poorly water soluble agent, and having improved fluidity and / or palatability. The syrup of the present invention has a plasma concentration profile equivalent to or greater than, or is biologically equivalent to, a capsule containing the same amount of alectinib or a salt thereof as the syrup, or has an enhanced oral bioavailability compared to a capsule containing the same amount of alectinib or a salt thereof as the syrup.

This invention belongs to the field of animal model technology and discloses a method and system for constructing a NMOSD mouse model. The method includes extracting NMO-IgG from patient plasma replacement fluid, actively immunizing mice with an AQP4 p201-220 peptide emulsion, and injecting NMO-IgG to establish an NMOSD animal model. This invention uses active immunization with AQP4 p201-220 peptide combined with an antigen adjuvant, and then injects patient-derived NMO-IgG on this basis. Compared with other existing animal models, the characteristic clinical manifestations of NMOSD, including the detection of peripheral blood AQP4-IgG autoantibodies and the characteristic loss of AQP4 and GFAP proteins in the retina, optic nerve, and spinal cord, are more significant, more objectively reflecting the disease characteristics of NMOSD and providing a new research platform for related studies.

The application discloses a CKD and IgAN early detection method based on blood mass spectrum analysis, utilizes liquid chromatography-tandem mass spectrometry technology to detect 24 kinds of compounds of a plasma sample in a targeted manner, utilizes a logic regression to establish an early detection model of CKD and IgAN, and verifies the prediction accuracy of CKD and IgAN in a cohort. Through analysis of plasma samples of healthy controls and CKD patients (including IgAN and non-IgAN patients), it is proved that the melatonin or melatonin+tryptophan level in the plasma is an effective method for detecting early CKD, and the melatonin, tryptophan, indole-3-lactic acid, indole-3-carboxylic acid, kynurenic acid and indole-3-methyl aldehyde are effective methods for detecting early IgAN. The application provides effective blood markers for early detection of CKD and IgAN.

The present application relates to a kind of melancholic depression plasma biomarker kit detection method, for detecting the plasma biomarker of melancholic depression.The present application provides a kind of application method by detecting plasma adiponectin (Adiponectin) protein as the application method of melancholic depression biomarker, the present application method is used for the subtype classification diagnosis of melancholic depression for non-diagnostic purposes, improve the sensitivity and specificity of melancholic depression screening.

Disclosed is a method for diagnosing a cancer health status, or a change in cancer health status, or for diagnosing a risk of cancer change or presence in a patient, comprising determining in a plasma sample from the patient one or more biomarker values corresponding to a complex structure containing alpha-1 antitrypsin (A1AT), and based on the biomarker values, determining the patient as suffering or not suffering from cancer, or having or not having a change in cancer health status, or having or not having a risk of cancer, wherein the cancer is selected from the group consisting of hepatocellular carcinoma (HCC), ovarian cancer (OC), and breast cancer (BC).

The application belongs to the technical field of in-vitro diagnostic reagents, and particularly relates to thrombelastography quality control products and a preparation method and application in preparation of coagulation detection products, a coagulation detection product and a coagulation detection method. The application realizes high adhesion of quality control product coagulation parameters and clinical actual measurement values by optimizing plasma proportioning and screening special excipients, can simulate six typical clinical coagulation states from normal coagulation to low coagulation, high coagulation, fibrinogen abnormality, DIC and the like, and simultaneously has the characteristics of simple preparation process and excellent long-term stability.

The application provides a stem cell collector, which comprises a body and two extrusion devices, the body has two inner cavities, a front side wall of the body is formed with two extrusion surfaces, the extrusion surfaces are provided with openings in communication with the inner cavities, and the two extrusion devices are arranged on the body and correspond to one extrusion surface respectively. The extrusion device comprises an extrusion plate, a first moving assembly, a partition plate, a second moving assembly, an extrusion block, a third moving assembly and a driving mechanism. The stem cell collector can automatically extrude a blood bag, facilitates the collection of a solution containing a plasma layer, a white blood cell and platelet layer and a small part of a red blood cell layer, reduces the mixing of the red blood cell layer, improves the collection efficiency and brings convenience for the collection of stem cells.

This invention provides a drug for antagonizing bacterial endotoxins, its preparation method, and its application, belonging to the biomedical field. The composition consists of 25-55 parts of dried powdered traditional Chinese medicine extract, 25-70 parts of mixed essential oil powder, and 40-90 parts of lentinan powder. The traditional Chinese medicine extract is prepared by decoction of Scutellaria baicalensis, Lonicera japonica, Forsythia suspensa, and Isatis indigotica under reduced pressure at low temperature and spray drying. The mixed essential oil powder is prepared by encapsulating peppermint oil and eucalyptus oil with gelatin and hydroxypropyl cellulose and then spray drying under high pressure. This invention, through specific formulation and processing, significantly enhances the synergistic antagonistic effect of each component against endotoxins. Experiments show that this composition exhibits antagonistic activity far superior to ibuprofen in vitro; in vivo, it significantly reduces the endotoxin content in the plasma of 817 broiler chickens, rapidly alleviates LPS-induced fever and diarrhea, and improves decreased growth performance. Therefore, this invention is of great significance for reducing antibiotic dependence and improving the efficiency of livestock and poultry farming.

The present application belongs to the field of photochemical therapy, and particularly relates to a method for photochemical treatment of riboflavin based on multi-wavelength LED and application thereof in treatment of graft-versus-host disease. The present application selects different wavelength LED combinations as light sources to optimize the riboflavin photochemical method, controls the light intensity at 1000-25000 μW / cm², controls the irradiation time at 5-15 minutes, and controls the riboflavin concentration at 20-150 μM, thereby significantly improving the photochemical reaction effect. The method can efficiently induce PBMC apoptosis in a plasma environment, significantly reduces the levels of key pro-inflammatory cytokines such as TNF-α, IL-6 and IFN-γ, and has no significant influence on platelets, hemoglobin and blood clotting function, thereby providing a safe and controllable new cell preparation method for GVHD treatment.

The present invention relates to a method for producing thrombin from a thromboplastin source using a given BaSO4 reagent as an adsorbent for prothrombin, and a method for assessing the suitability of a given BaSO4 reagent for the preparation of thrombin. In at least one embodiment, the method comprises contacting a sample of the given BaSO4 reagent with a thromboplastin source to obtain BaSO4-adsorbed thromboplastin, and subsequently assessing the procoagulant activity of the BaSO4-adsorbed thromboplastin. In another embodiment, the method comprises the step of assessing the procoagulant activity relative to normal mammalian plasma.

The application relates to application of BDNF as a biomarker in prenatal prediction of postpartum depression morbidity risk. The mBDNF and proBDNF levels in cerebrospinal fluid and plasma can be used as independent markers for prediction of postpartum depression morbidity risk, and the plasma mBDNF or cerebrospinal fluid proBDNF level can be used for prediction of postpartum depression morbidity risk through prenatal detection, which is helpful for prediction, early identification and timely intervention of postpartum depression and reduction of harm.

Disclosed is a method for diagnosing a cancer health state, or a change in cancer health state in a patient, or for diagnosing a risk of the change or presence of a cancer in a patient, comprising determining, in a plasma sample from said patient, one or more biomarker values that correspond to transthyretin-containing complex structures, and assigning the patient as having or not having cancer, or having or not having a change in cancer health state, or having or not having a risk of cancer based on said biomarker values, wherein said cancer is preferably lung cancer (LC).

This document provides methods and materials involved in assessing mammals with acute decompensated heart failure (ADHF), as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of plasma CNP and the level of urinary CNP to determine whether or not a mammal is developing or likely to develop more severe ADHF, as well as methods and materials for using the level of plasma CNP and the level of urinary CNP to identify patients having an increased likelihood of experiencing a poor outcome are provided.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to a PSD-95 PDZ2 peptidomimetic inhibitor and application thereof. A series of compounds are designed and synthesized by taking a tetrapeptide ETAV as a template, a structure-activity relationship of the compounds with PSD-95 PDZ2 is systematically studied, and an optimal compound 32-2, i.e., the PSD-95 PDZ2 peptidomimetic inhibitor, is screened, a structural formula of which is shown as formula (I), the PSD-95 PDZ2 peptidomimetic inhibitor has very excellent plasma stability, and exhibits significant neuroprotective activity in in-vivo and in-vitro biological activity evaluation, significantly reduces cerebral infarction caused by cerebral ischemia-reperfusion injury, and can be used for preparing a drug for treating ischemic stroke. (I).

This utility model provides an ice-block type plasma bag suspension device, including: a blood bag body, a suspension mechanism, a clamping mechanism, and a positioning adjustment device. The suspension mechanism is mounted on an external support device, and a clamping mechanism is installed on the suspension mechanism. One end of the clamping mechanism is a clamping end, and the other end is an adjustment end. A connecting pipe is connected to the upper end of the blood bag body, and a protruding ring protrudes from the outer wall of the connecting pipe. The connecting pipe can be clamped by the clamping end of the clamping mechanism, and the protruding ring is supported by the clamping mechanism. The positioning adjustment device is adjustablely mounted on the suspension mechanism, and the output end of the positioning adjustment device restricts the opening of the clamping end of the clamping mechanism by acting on it. This ice-block type plasma bag suspension device provides precise position support and positioning for the adjustment mechanism through the fixing of the inner toothed ring and the vertical movement of the outer toothed ring, combined with the design of different heights of the support arm.

This invention discloses an endothelin A receptor antagonist-albumin fusion protein and its application in preventing and treating hypotension during anesthesia induction. The fusion protein is formed by chemically coupling BQ-123 with human serum albumin (HSA). BQFu significantly enhances its antihypertensive effect by prolonging the half-life of BQ-123 and improving plasma stability. Experiments show that BQFu dose-dependently inhibits the decrease in mean arterial pressure (MAP) in a propofol-induced hypotension model, with a sustained and stable effect in the high-dose group (30 mpk), shortening the recovery time to 20.8 ± 10.5 min, while maintaining BQ-123 activity. This invention provides a long-acting and safe prevention and treatment strategy for hypotension during anesthesia induction.